Assessment of Treatment Strategies for Drug-Resistant Tuberculosis Across Various Regions: A Systematic Review and Meta-Analysis - Takeaways - MDSpire

Assessment of Treatment Strategies for Drug-Resistant Tuberculosis Across Various Regions: A Systematic Review and Meta-Analysis

  • By

  • Xiaonan Geng

  • Fan Zhang

  • Ruichao Liu

  • Fuzhen Zhang

  • Ziwen Li

  • Liang Li

  • January 21, 2026

  • 0 min

Share

  • 1

    Drug-resistant tuberculosis (DR-TB) poses a significant public health threat, particularly multidrug-resistant (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB).

  • 2

    The global incidence of MDR/RR-TB has stabilized, with approximately 400,000 cases reported in 2023, accounting for 3.2% of new TB cases.

  • 3

    The WHO introduced an all-oral regimen for MDR/RR-TB treatment in 2018, improving patient outcomes compared to previous regimens that included injectables.

  • 4

    The treatment success rate for MDR/RR-TB has improved to 68% in 2024, but remains low, with many patients experiencing adverse events during treatment.

  • 5

    A systematic review and meta-analysis were conducted to assess the efficacy and safety of DR-TB treatment regimens across different regions from 2006 to 2025.

Original Source(s)

Assessment of Treatment Strategies for Drug-Resistant Tuberculosis Across Various Regions: A Systematic Review and Meta-Analysis

  • by Xiaonan Geng, Fan Zhang, Ruichao Liu, Fuzhen Zhang, Ziwen Li, Liang Li

  • January 21, 2026

Related Content

Case Study and Literature Analysis of Multidrug-Resistant Tuberculosis Affecting Breast and Uterine Adnexa

Enhancing Diagnosis of Drug-Resistant Tuberculosis: Evaluating the Cost-Effectiveness of Rapid Molecular and Phenotypic Testing in South Africa

Self-Management Strategies and Sputum Clearance in Pulmonary Tuberculosis: A Prospective Investigation